• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cibus Inc.

    3/24/25 5:22:06 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials
    Get the next $CBUS alert in real time by email
    S-8 1 d927420ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 24, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Cibus, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   27-1967997

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    6455 Nancy Ridge Drive

    San Diego, CA 92121

    (Address of Principal Executive Offices, Including Zip Code)

    CIBUS, INC. 2017 OMNIBUS INCENTIVE PLAN

    (Full title of the plan)

    Peter Beetham

    Interim Chief Executive Officer

    6455 Nancy Ridge Drive

    San Diego, CA 92121

    (Name and address of agent for service)

    (858) 450-0008

    (Telephone number, including area code, of agent for service)

    Copies to:

    Peter E. Devlin

    Erik B. Lundgren

    Jones Day

    250 Vesey Street

    New York, NY 10281

    (212) 326-3939

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E

    Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed for the purpose of registering an additional 4,000,000 shares of Class A common stock, par value $0.0001 per share, of Cibus, Inc. (the “Company” or the “Registrant”) authorized for issuance pursuant to the Cibus, Inc. 2017 Omnibus Incentive Plan, as amended, which is the same class as the securities previously registered for issuance thereunder on effective Registration Statements on Form S-8 filed with the Securities and Exchange Commission on July 20, 2017 (File No. 333-219382), May 9, 2019 (File No. 333-231336), July 16, 2021 (File No. 333-257972), March 2, 2023 (File No. 333-270245), May 24, 2023 (File No. 333-272177) and June 30, 2023 (File No. 333-273069) (collectively, the “Prior Registration Statements”). The contents of the Prior Registration Statements are incorporated by reference into this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

     

      •  

    the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (including the information in Part III incorporated therein by reference from the Company’s Definitive Proxy Statement on Schedule 14A for the year ended December 31, 2024);

     

      •  

    the Company’s Current Reports on Form 8-K filed on January 22, 2025 and February 28, 2025 (in each case, excluding any information furnished and not filed with the Commission); and

     

      •  

    the description of the Company’s Class  A Common Stock contained in our Registration Statement on Form 8-A, filed on July 20, 2017, as the description therein has been updated and superseded by the description of securities contained in Exhibit 99.1 to our Current Report on Form 8-K filed with the SEC on June 29, 2023, including any amendments or reports filed for the purpose of updating the description.

    In addition, all other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such reports or documents.

    Any statement contained herein, or in a document incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


    Item 8. Exhibits.

     

    Exhibit
    No.
      

    Description of Exhibit

      4.1    Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the Commission on June 1, 2023).
      4.2    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed with the Commission on June 1, 2023).
      5.1*    Opinion of Jones Day.
     23.1*    Consent of BDO USA, P.C.
     23.2*    Consent of Jones Day (included in Exhibit 5.1).
     24.1*    Power of Attorney (included in the signature page to this Registration Statement).
     99.1    Cibus, Inc. 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.7 of the Company’s Current Report on Form 8-K filed with the SEC on June 1, 2023).
     99.2    Cibus, Inc. (f/k/a Calyxt, Inc.) 2017 Stock Option Sub-Plan for French Employees and Directors (incorporated by reference to Exhibit 10.21 to the Company’s Registration Statement on Form S-1 filed on July 3, 2017 (File No. 333—218924)).
     99.3    Form of Stock Option Agreement pursuant to the Cibus, Inc. (f/k/a Calyxt, Inc.) 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.3 the Company’s Form 10-Q for the quarter ended June 30, 2020).
     99.4    Form of Restrictive Stock Unit (Employees) pursuant to the Cibus, Inc. (f/k/a Calyxt, Inc.) 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.18 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024).
     99.5    Form of Stock Option Agreement (Employees) pursuant to the Cibus, Inc. (f/k/a Calyxt, Inc.) 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.19 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024).
     99.6    Form of Restricted Stock Unit Agreement (Directors) pursuant to the Cibus, Inc. (f/k/a Calyxt, Inc.) 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024).
     99.7    Form of Stock Option Agreement (Directors) pursuant to the Cibus, Inc. (f/k/a Calyxt, Inc.) 2017 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.21 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024).
     99.8*    Form of Restricted Stock Agreement (incorporated by reference to Exhibit 99.10 to the Company’s Registration Statement on Form S-8 filed with the SEC on June 30, 2023).
    107*    Filing Fee Table

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 24, 2025.

     

    Cibus, Inc.

     

    By:   /s/ Peter Beetham
    Name:   Peter Beetham
    Title:   Interim Chief Executive Officer

    POWER OF ATTORNEY

    The undersigned directors and officers of Cibus, Inc. hereby appoint each of Peter Beetham and Cornelis (Carlo) Broos as attorneys-in-fact for the undersigned, with full power of substitution for, and in the name, place and stead of the undersigned, to sign and file with the Securities and Exchange Commission under the Securities Act of 1933, any and all amendments (including post-effective amendments) and exhibits to this Registration Statement on Form S-8 and any and all applications and other documents to be filed with the Securities and Exchange Commission pertaining to the registration of the securities covered hereby, with full power and authority to do and perform any and all acts and things whatsoever requisite and necessary or desirable, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated below.

     

    Signature

      

    Title

     

    Date

    /s/ Peter Beetham

    Peter Beetham

      

    Interim Chief Executive Officer and Director

    (Principal Executive Officer)

      March 24, 2025

    /s/ Cornelis (Carlo) Broos

    Cornelis (Carlo) Broos

      

    Interim Chief Financial Officer

    (Principal Financial and Accounting Officer)

      March 24, 2025

    /s/ Rory Riggs

    Rory Riggs

       Chairman of the Board of Directors   March 24, 2025

    /s/ Mark Finn

    Mark Finn

       Director   March 24, 2025

    /s/ Jean-Pierre Lehmann

    Jean-Pierre Lehmann

       Director   March 24, 2025

    /s/ Gerhard Prante

    Gerhard Prante

       Director   March 24, 2025

    /s/ Keith Walker

    Keith Walker

       Director   March 24, 2025

    /s/ August Moretti

    August Moretti

       Director   March 24, 2025
    Get the next $CBUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CBUS

    DatePrice TargetRatingAnalyst
    7/29/2024$25.00Buy
    Alliance Global Partners
    7/19/2024$22.00Buy
    Canaccord Genuity
    10/9/2023$25.00Buy
    H.C. Wainwright
    7/19/2023$30.00Buy
    Canaccord Genuity
    More analyst ratings

    $CBUS
    Financials

    Live finance-specific insights

    See more
    • Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

      Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

      5/8/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call

      SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2025 financial results on Thursday, May 8, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2025 Results Conference Call Event Date: Thursday, May 8, 2025Time: 4:30 p.m. ETParticipant Numbers: +1-833-316-1983 (U.S.), +1-785-838-9310 (International)The c

      4/25/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call

      SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2024 Results Conference Call Event Date: Thursday, March 20, 2025         Time: 4:30 p.m. ET         Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317

      3/11/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cibus to Participate in Alliance Global Partner's Annual Virtual Healthcare Company Showcase

      SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Peter Beetham, Co-Founder, President, and Interim Chief Executive Officer, will host a presentation at the AGP Annual Virtual Healthcare Company Showcase. During the presentation, Dr. Beetham will discuss the Company's progress in advancing its gene-editing technology platform, recent regulatory developments supporting agricultural innovation, and Cibus' commercialization strategy for its productivity trait pipeline. Pr

      5/19/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025

      Rice business momentum builds with Cibus' first stacked gene edited herbicide tolerance traits, which the Company believes is an industry first; On track for 2027 targeted commercial launch of HT1 and HT3 traits with customer germplasm integration underway across multiple markets Positive regulatory decision for Cibus' Rice traits HT1 and HT3 in Ecuador; the Ministry of Agriculture and Livestock in Ecuador determined that the Company's HT1 and HT3 Rice traits are equivalent to those developed through conventional breeding Disease resistance program advances with positive Sclerotinia data for multiple modes of action against Sclerotinia in Canola; Cibus' time bound and predictable RTDS tech

      5/8/25 4:05:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Ecuador Approves Cibus Herbicide Tolerance Traits as Equivalent to Conventional Breeding

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, announced today that the Ministry of Agriculture and Livestock in Ecuador has determined that Rice cultivars containing Cibus' herbicide tolerance Rice traits (HT1 and HT3) are equivalent to those developed through conventional breeding and subject to the same regulations as conventional seed in accordance with the provisions of the Organic Law of Agrobiodiversity, Seeds and Promotion of Sustainable Agriculture and its Regulations. The Rice trait products reviewed were developed utilizing Cibus' Rapi

      5/7/25 7:00:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Research Sauer Noel was granted 11,750 shares, increasing direct ownership by 13% to 105,480 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      3/28/25 4:54:46 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • New insider Sauer Noel claimed ownership of 93,730 shares (SEC Form 3)

      3 - Cibus, Inc. (0001705843) (Issuer)

      3/28/25 4:50:18 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • CLO, Gen Csl & Secy Stokes Jason was granted 28,250 shares, increasing direct ownership by 28% to 127,669 units (SEC Form 4)

      4 - Cibus, Inc. (0001705843) (Issuer)

      3/28/25 4:38:32 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

      EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools, today announced the appointment of Simon Harnest, MSc, BSc, as Chief Financial Officer. This key addition comes at a pivotal moment for Totus as the company prepares to advance its clinical-stage program following encouraging results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor. "The addition of Simon, with over 15 years' experience in private capital markets strategy and IPO processes, comes at the right time for Totus as we advance our clinical-stage and discovery programs," said

      1/28/25 8:00:00 AM ET
      $CBUS
      $CLLS
      $MGX
      $CLXT
      Agricultural Chemicals
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jim Collins to Join Cibus Board of Directors

      Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. "Jim brings to Cibus immense knowledge and strategic vision on the direction of the future role and use of Gene Editing in agriculture," said Mark Finn, Chair of the Audit Committee. "Jim's experience leading one of the largest agricultural and seed companies will gi

      9/18/23 5:23:58 PM ET
      $ADM
      $CBUS
      Packaged Foods
      Consumer Staples
      Agricultural Chemicals
      Industrials
    • Steve Berreth Appointed as General Counsel and Corporate Secretary

      SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, announced today the appointment of Steve Berreth as General Counsel and Corporate Secretary for the corporation. Mr. Berreth was previously Vice President, General Counsel and Secretary for Syngenta Crop Protection LLC, the North American Subsidiary of Syngenta AG, one of the world's largest biotechnology agribusinesses and one of the largest crop protection chemical and seed businesses in the world. He was a member of the Syngenta global legal and compliance leadership teams and led the North American le

      8/3/23 12:30:00 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Cibus Global with a new price target

      Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

      7/29/24 7:49:52 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Canaccord Genuity resumed coverage on Cibus Global with a new price target

      Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00

      7/19/24 8:34:00 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • H.C. Wainwright initiated coverage on Cibus Global with a new price target

      H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00

      10/9/23 8:32:05 AM ET
      $CBUS
      Agricultural Chemicals
      Industrials

    $CBUS
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Cibus Inc.

      SCHEDULE 13G - Cibus, Inc. (0001705843) (Subject)

      5/15/25 3:10:07 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • SEC Form 10-Q filed by Cibus Inc.

      10-Q - Cibus, Inc. (0001705843) (Filer)

      5/8/25 4:35:08 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials
    • Cibus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cibus, Inc. (0001705843) (Filer)

      5/8/25 4:19:03 PM ET
      $CBUS
      Agricultural Chemicals
      Industrials